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A B S T R A C T 
Glioblastoma (GBM) is the most common and malignant primary brain tumor in adults. The current 
treatment regimes for glioblastoma demonstrated a low efficiency and offer a poor 
prognosis.Advancements in conventional treatment strategies have only yielded modest 
improvements in overall survival. The heat shockproteins, heme oxygenase-1 (HO-1) and Hsp90, 
serve these pivotal roles in tumor cells and have been identified as effective targets for developing 
therapeutics. This topic review summarizes the current preclinical and clinical evidences and 
rationale to define the potential of HO-1 and Hsp90 in GBM progression and chemoresistance. 
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1. Introduction 
Infiltrative gliomas are the most common primary intracranial neoplasms, 
accounting for 40% of all primary and 78% of all malignant central 
nervous system tumours (1).The term “astrocytoma” is normally referred 
to “gliomas” by researchers worldwide.Glial cells have fundamental roles 
by providing essential support such as immune protection, mechanical 
support, nutrients and oxygen supply to neuronal cells. These cells also 
assist neurons to mediate complex processes as neurotransmission, signal 
transduction and providing more structures for the migration of neurons 
into their respective networks during development (2). 
Particular attention is focused on grade IV astrocytoma, synonymous of 
common name Glioblastoma Multiforme or simply Glioblastoma (GBM) 
in the current World Health Organization (WHO) scheme. The term GBM 
was introduced by Mallory in 1914 (3) and commonly accepted in the 
surgical neuropathology lexicon by Bailey and Cushing in 1926 (4). 
Distinguished features of GBM are microvascular proliferation (MVP), 
loosely defined to include endothelial hypertrophy, endothelial  
 
hyperplasia and glomeruloid vessels, and/or necrosis (5). Glioblastoma 
may arise through two distinct pathways of neoplastic progression. 
Tumours progressing from lower-grade (II or III) astrocytic tumours are 
termed secondary or type 1 GBMs, display both well-differentiated and 
poorly differentiated foci. Secondary GBMs occurring in younger patients 
(fifth to sixth decade), with time to progression from months to decades. 
In contrast, primary type 2 GBMs develop in older individuals (sixth to 
seventh decade), have short clinical histories and arise de novo without 
any evidence of a lower-grade precursor. Genetic features of primary 
GBMs are relatively high frequencies of Epithelial Growth Factor 
Receptor (EGFR) amplification, Phosphatase and tensin homolog (PTEN) 
deletion and cyclin-dependent kinase Inhibitor 2A(CDKN2A) loss, while 
secondary GBMs often contain TP53 mutations (6). GBMs comprise a 
morphologically highly heterogeneous neoplasm, as designation 
multiforme implies. In other words, the cellular composition can vary 
widely and mixed histologic features are typical (5). Three GBM variants 
are recognized as distinct pathologies in the current WHO classification: 
conventional GBM, giant cell GBM (GC-GBM) and gliosarcoma (GC).  
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2. Conventional GBM 
Its cellular composition is heterogeneous and may include fibrillary, 
gemistocytic, and/or occasional giant cells (GCs). Neoplastic fibrillary 
astrocytes contain enlarged, irregularly shaped, hyperchromatic nuclei and 
variable glia fibrillary acidic protein (GFAP)-immunoreactive processes 
that form a loose, fibrillary matrix. Gemistocytes were first described by 
Franz Nissl as glia (gemaestete glia) with voluminous cytoplasm (7). 
Gemistocytic astrocytes contain full, glazed, eosinophilic GFAP-
immunoreactive cytoplasm. Although gemistocytes may be found in all 
grades of astrocytoma, gemistocytic astrocytoma is recognized as a 
distinct variant only of diffuse astrocytoma. Gemistocytic astrocytoma is 
defined by WHO as an astrocytoma composed of more than 20% 
gemistocytes (5).Different reports have defined the percentage of 
gemystocytes present in a tumor (gemistocytic index) and correlated it 
with patient outcomes. Gemistocytic astrocytoma with greater than 5% 
gemistocytes have been reported to progress more rapidly to GBM (8).A 
rare form of this kind of tumor is Granular cell astrocytomas composed of 
large cells with a lot of glanular acid-Schiff-positive cytoplasm (5, 9-12). 
Most granular cell astrocytomas are GFAP positive and may show non-
specifically cytoplasmic epithelial membrane antigen but they do not have 
a cytokeratin immunoreactivity (9, 10). These tumours may also have 
TP53 mutations, high-frequency loss of heterozygosis at 9p, 10q and 17p, 
and less frequent loss of heterozygosis at 1p and 19q(11). Furthermore, 
Brat at al. found that these tumours were more aggressive than non-
granular cell astrocytoma of the same grade (9).  
 
3. Giant cell GBM (GC-GBM) 
Giant cell GBM constitutes approximately 5% of GBMs and it is 
recognized as a distinct pathology in the WHO 2000 classification (5). 
The tumor cells are considerably enlarged and bizarre, often appearing 
multinucleated. Giant cell GBMs are typically well-circumscribed masses 
that appear in younger patients.  
Whereas EGFR amplification and CDKN2A deletion are rare in 
comparison to conventional GBMs, the molecular genetic features include 
relatively high frequencies of TP53 mutations (75%-90%) and PTEN 
deletion (5%-30%); thus, GC-GBMs contain clinical and molecular 
genetic characteristics of primary and secondary GBMs and occupy and 
intermediate position between these two (5, 13, 14). Fujita et al. and 
Maeda et al have described a potential molecular mechanism for GC 
formation (15, 16). Investigators have demonstrated that the molecular 
alteration causing collapse of cytoplasmic rift in cultured multinucleated 
GCs is loss of Aurora-B kinase function. It is demonstrated that Aurora-B 
kinase is overexpressed in astrocytomas in general, with mRNA and 
protein levels correlating with WHO grade (17). 
 
4. Gliosarcoma (GS) 
Gliosarcoma constitutes approximately 2% of GBMs and is equally 
recognized ad a distinct pathology in the WHO 2000 classification(5). 
Main features of these tumours are circumscribed, biphasic growth pattern 
with clearly identifiable glial and metaplastic mesenchymal components. 
The glial component of GS may show any previously described 
cytological characteristic and is typically immunoreactive for GFAP. The 
mesenchymal component may show a high variety of morphologic 
appearances with differentiation along fibroblastic, cartilagineous, 
osseous, smooth and striated muscle, and adipose lines (5). In addition to 
sarcomatous differentiation, an epithelial metaplasia may also occur in GS 
or conventional GBM, including cases of keratinizing squamous or 
glandular differentiation. These features allow establishing a differential 
diagnosis of metastatic carcinoma.  
The metaplastic component in GS is neoplastic and frequently allows 
cytogenetic and molecular abnormalities similar to those found in the glial 
component. GSs are genetically similar to primary GBMs with TP53 
mutations, PTEN and CDKN2A deletions demonstrated for 20-40% of 
tumours. An exception is the relative infrequency of EGFR amplification 
in these tumours (5, 18).  
 
5. Other variants of GBM 
It is possible to identify additional variants of GBM that have been 
published in WHO 2000 classification scheme. These include small cell 
astrocytomas (SCAs), glioblastoma with oligodendroglial features (GBM-
O) and GBM with primary neuronal feature (primitive neuroectodermal 
tumor [PNET]-like)(5). These variant tumours demonstrated a significant 
morphologic junction with other recognized pathologies: to make and 
accurate histophatologic and molecular genetic characterization, it is 
important an identification of molecular genetic alterations and its 
association with responsiveness to therapy and an improved 
prognosis.Small cell astrocytoma is a variant of GBM with an important 
overlap with anaplastic oligodendroglioma (AO) carrying out a classical 
hematoxylin-eosin-stained sections(19, 20).The histopathologic features 
of this tumor are its bland nuclear cytology and bizarre mitotic activity. It 
is composed of a large number of astrocytes with small, uniformly oval 
nuclei with mild hyperchromasia and minimal distinguishable cytoplasm. 
Furthermore, SCA can show cortical infiltration and secondary structures, 
including perineuronal satellitosis.  
 
6. Management and therapy 
To date no current treatment is curative and it consists in maximal surgical 
resection, radiotherapy and concomitant adjuvant chemotherapy with 
temozolomide (21, 22).The use of radiotherapy is now widespread and, in 
particular, the addition to surgery increases the survival of patients (23, 
24); nevertheless the responsiveness of GBM to radiotherapy varies.  
Furthermore, radiosensitizer (drug that makes tumor cells more sensitive 
to radiation therapy) such as newer chemotherapeutic agents (25), targeted 
molecular agents (26, 27) and antiangiogenic agents may increase the 
therapeutic effect of radiotherapy (15, 28). However, the useof 
radiotherapy for recurrent GBM is controversial. 
Currently, there not exists a defined optimal chemotherapeutic regimen 
for GBM, even thought adjuvant chemotherapy appears to produce a 
significant benefit in more than 25% of patients (21, 29-34). The agents 
currently used include Temozolomide, nitrosoureas (eg. Carmustine), 
O(6)-methylguanine-DNA methyltransferase (MGMT)inhibitors (eg. O6-
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benzylguanine), Cisplatin, Bevacizumab (alone or with Irinotecan for 
recurrent glioma). 
New therapies include gene therapy, peptide and dendritic cell vaccines, 
synthetic chlototoxins, radiolabeled drugs and antibody (35-40). 
From a chirurgical point of view and because GBM cannot be cured 
surgically, the surgical goals are to establish a pathologic diagnosis, to 
relieve any mass effect, to achieve a gross total resection to facilitate 
adjuvant therapy (41). The extent of surgery has been demonstrated in a 
number of studies to affect length survival; surgical options include gross 
total resection and subtotal resection: the first one has a better survival. 
 
7. Heat Shock Proteins and cancer 
In the mid 1950‟s the Nobel Prize Laureate Christian B. Anfinsen from 
his research on the folding of ribonuclease A (42), began to concentrate 
on the problem of the relationship between structure and function in 
enzymes. On the basis of studies on ribonuclease, he proposed that the 
information determining the tertiary structure of a protein resides in the 
chemistry of its amino acid sequence. He also elegantly showed that, after 
cleavage of disulfide bonds and disruption of tertiary structure, many 
proteins could spontaneously refold to their native forms (43). However, 
in the following years several studies demonstrated that this assertion is 
not valid for all synthetized proteins thus suggesting that some proteins 
may violate the Anfinsen‟s dogma (44). In fact, some highly specific 
„steric chaperones‟ do convey unique structural (steric) information onto 
proteins, which cannot be folded spontaneously. This finding changed 
dramatically the way of studying protein synthesis and their maturation 
following the translation process. In addition, further studies demonstrated 
that impairment of the chaperone machinery might lead to various 
pathologies including cancer. We will review the role of two Hsps, which 
have recently offer new insights and potential therapeutic potential. 
 
8. Role of Heme oxygenase-1 (Hsp 32) 
Heme oxygenases (HO) catalyze the degradation of heme into biliverdin, 
carbon monoxide (CO) and ferric iron (45-51). Heme functions as the 
prosthetic group in hemoproteins, e.g., nitric oxide synthase, 
cyclooxygenases, soluble guanylate cyclase, cytochrome P450, 
peroxidase, and catalase and since HO is the sole physiological pathway 
of heme degradation. It consequently plays a critical role in the regulation 
of cellular heme-dependent enzyme levels (52-56). To date, two HO 
isoforms have been shown to be catalytically active in heme degradation 
and each is encoded by a different gene (46, 57). Heme oxygenase-1 (HO-
1) is expressed at low levels under basal conditions and it is induced by 
polyphenols (58-64), statins (65), metals (66-69) and a variety of stimuli 
such as inflammation, oxidative stress, hyperoxia, hypoxia and trauma 
(50, 70-76). Such upregulation represents an intrinsic defence mechanism 
to maintain cellular homeostasis and enhance cell survival (77-80). In 
particular, HO-1 is considered to play a major role as an essential survival 
factor, protecting against chemotherapy-induced reactive oxygen species 
(ROS) increase (72, 81-85).  
 
 
In particular, HO-1 overexpression is implicated in tumor genesis, growth 
and resistance to chemo- and radiotherapy in a lot of cancers (86-90). In 
1996, Shibahara et al. demonstrated that expression level ofHO-1 mRNA 
is higher in brain tumours compared to the brain tissue (91). Furthermore, 
they showed that HO-1 mRNA expression is higher in human 
glioblastoma cell line T98G after a treatment with three types of Nitric 
Oxide (NO) donors: although this has not been shown any increase ofHO-
2 mRNA expression (92).Researchers showed that macrophages play a 
key role in angiogenesis of malignant formations through the infiltration 
process (93-96).  Leading an immunostaining on gliomas samples has 
been shown that the number of infiltrating macrophages and density of 
small blood vessels is higher in glioblastomas compared to astrocytomas 
or anaplastic astrocytomas. HO-1 is also associated with the activation of 
macrophages. In fact, the expression of mRNA coding for HO-1 correlates 
with macrophage infiltration. In addition, macrophages are positively 
stained with anti-HO-1 antibody: this result has led to the hypothesis of 
using HO-1 as a marker of macrophage infiltration and neovascularization 
in human gliomas (97). 
Lu et al. demonstrated a correlation between HO-1 and human gliomas, in 
particular using HO-1 as possible novel therapeutic target. They showed 
the relationship between Nuclear factor E2-Related Factor 2 (Nrf2) and 
osteopontin-stimulated HO-1 expression: briefly, Nrf2 activation is 
essential for osteopontin-stimulated HO-1 expression, based on the 
evidence that Nrf2 small interfering RNA (siRNA) inhibits the 
enhancement of osteopontin-induced migration; moreover, osteopontin 
stimulated Nrf2 accumulation in nucleus and increased Nrf2-DNA 
binding activity. Taken all together, these results propose that Nrf2 
activation is required for osteopontin-HO-1 expression and cell migration 
in human glioma. This study presents a novel mechanism of osteopontin-
directed migration and HO-1 up-regulation in human glioma cells by 
activation of Protein kinase B (Akt),Extracellular signal–Regulated 
Kinases (ERK) and Nrf2-dependent pathway (98). Pan et al. worked on 
the involvement of Nrf2-Antioxidant Responsive Element (ARE) pathway 
in regulation of apoptosis in human glioblastoma cell U251: they showed 
that after increasing expression of Nrf2, the apoptosis was reduced with an 
up-regulation of expression of HO-1, Bcl-2/Bax and a decreased 
expression and activity of Caspases 3 and 9. The apoptosis rate was 
enhanced decreasing Nrf2 expression accompanied with a down-regulated 
expression of HO-1, Bcl-2/Bax and an increased expression and activity 
of Caspases 3 and 9 (99). 
There are conflicting reports about the role of HO-1 plays in tumor 
initiation and progression, ever since it has been demonstrated that can 
play a role as tumor-promoter or inhibitor on tumor progression (86, 100). 
Gandini et al. produce strong evidence of HO-1 overexpression in human 
gliomas compared with non-malignant samples. Moreover, this expression 
was associated with a worse prognosis in patients with grade II and III 
astrocytoma. They suggested that the enzyme could be involved in tumor 
proliferation and point to a pro-tumoral role of HO-1 in glioma 
progression. (101) 
Furthermore, some studies demonstrated that HO-1 has a cytoprotective 
role in glioma and showed evidence that the enzyme could be a potential 
therapeutic target in this cancer type. (98, 102) Further, a lot of groups 
showed that a decrease (102, 103) or an increase (104, 105) in HO-1 is 
necessary for the anti-cancer effects of many compounds on human 
glioma cells (Table 1).  
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Table 1: Heat Shock Protein 32 (HSP 32) in Glioblastoma 
Multiforme (GBM) 
Expression of HSP32 
mRNA 







Inducible cell migration and 
invasion 
Increasing expression of 
Nrf2 
Reduced apoptosis with 
HO-1 and Bcl-2/Bax 
upregulated expression, 
decreased expression and 
activity of Caspases 3 and 9 
Cytoprotective role Potential therapeutic target 
 
9. Role of Hsp 90 and Glioblastoma 
Heat-shock-protein 90 (HSP90) is a molecular chaperone conserved and 
abundant in eukaryotic cell where this protein is an ubiquitous protein 
highly expressed in the cytosol, both in normal and stress conditions 
(106). This chaperones performs its “canonical” functions inside cells by 
forming cytosolic chaperoning machines (107) and is involved in the 
correct folding and conformational maturation of newly translated 
proteins, so called HSP90 client proteins, many of which are deregulated 
in glioblastomas (108, 109). Hsp90 is also involved in signal transduction 
and other key pathways critical for malignancy in several cancers (110-
112) and glioblastomas specifically (113).  Hsp90 can accumulate in 
cancer cells and is implicated in the carcinogenesis process for many 
reasons (114). This molecule favours tumorigenicity and is crucial to 
cancer cell growth and survival (115) by inhibiting programmed cell death 
and senescence (116). Hsp90 client proteins involved in its activities are 
many and varied and among them are included core mediators of 
glioblastoma‟s cellular growth like Akt kinase (117), endothelial nitric 
oxide synthase (eNOS), (109, 118) epidermal growth factor receptor 
(EGFR) and transforming growth factor-beta (TGF-beta) (119). Hsp90 
has interactions, for example, with a protein complex in which there is a 
mutant epidermal growth factor receptor, EGFRvIII, that is expressed in 
most glioblastomas and is associated with poor prognosis promoting an 
aggressive growth (120). Among the client protein of Hsp90 there are 
client kinases such as Protein Kinase C (PKC) that has been directly 
implicated in the proliferation of glioblastoma. PKC also activates Protein 
Kinase D family (PRKD), which consists of PRKD1, -2 and, -3 that could 
play a major role in glioblastoma growth (121). PKD2 regulates 
glioblastoma cell migration and invasion (122). Hsp90 also influences 
tumor neoangiogenesis because it stabilizes proteins important for the 
metabolism of endothelial cells such as Vascular Endothelial Growth 





Indeed it is suggested that Hsp90 regulating the stability of PRKD2, is 
implicated in the formation of new blood vessel involving up-regulation 
and secretion of VEGF-A (108).  
Recent works have claimed within glioblastomas the existence of small 
population of stem cell (124, 125), which are able to enable them to self-
renew and give rise to the heterogeneous mass that characterizes these 
brain tumours (117). This set of stem cell appears also to be responsible of 
chemotherapy resistance and higher clonogenic capacity.  The origin of 
these stem cells within neoplastic mass is not very clear; in fact they may 
arise from endogenous stem cells or from glioma cells that have 
undergone a block in differentiation (109). The aldehyde dehydrogenase 
(ALDH) is considered a marker of stem cell in many cancers and in 
particular in those of glioblastomas, were the same stem cells showed also 
an high expression of Hsp90 which proves its implication in many crucial 
mechanism of cell survival (126). Heat Shock Protein 90 is involved in a 
cytoprotective mechanism against cellular stressors such as DNA damage 
(127). For this reason several studies (128) have focused on alternative 
therapies for potentiating chemotherapy and X-ray irradiation using for 
example, Hsp90-inhibitors as antitumor agents in glioblastoma‟s therapy. 
It is showed that Geldanamycin interacts with the HSP90ATP-binding site 
to interfere in its interaction with client proteins (129) and 17-allylamino-
17-demethoxygeldanamycin, an analogous of Geldanamycin, inhibits 
growth and invasion of GBM tumor(117, 130). HSP90 inhibitors promote 
the degradation of HSP90-dependent oncoproteins finally leading to cell 
cycle arrest and cell death. 
Given the high proliferative capacity of glioblastoma cells and their 
resistance to current therapy it is necessary to introduce a multitargeted 
strategy that may be more effective. The HSP90 inhibition might be a 
good therapeutic strategy given that HSP90 client protein are protein 
known to deregulated in the neoplastic process of Glioblastoma(117) 
(Table 2). 
Table 2: Heat Shock Protein 90 (Hsp 90) in Glioblastoma  
Multiforme (GBM) 
“Canonical” function 
Chaperoning machine involved in 
correct folding and conformational 
maturation of protein 
Accumulation in cancer cells 
Stimulation of tumor genesis, 
cancer cell growth by inhibiting 
programmed cell death 
Interaction with EGFRvIII 
(mutant EGFR) 
Associated with poor prognosis, 
promoting and aggressive growth 
Influence on neoangiogenesis 
Stabilization of VEGF, NOS, 
PRKD2 with formation of new 
blood vessels 
Cytoprotective mechanism 
Potential therapeutic target: 
promote the degradation of 
HSP90-dependent oncoproteins 
finally leading to cell cycle arrest 
and cell death 
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10. Conclusion 
The treatment of glioblastoma remains an open challenge for modern 
medicine. Despite the discovery of new chemotherapic agents, no drug 
showed improvement in survival in phase III clinical trials. However, the 
increased knowledge of molecular characterization of various 
glioblastomas and patient clinical management has led to an increase in 
survival over the past 10 years. Furthermore, identification of new 
molecular targets (i.e. Hsps) involved in glioblastoma progression and the 
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